Charles River Laboratories and Magellan Stem Cells announced a collaboration on Oct. 13, 2026, bringing cGMP next-generation sequencing viral safety testing to Zelestrocel, Magellan’s off-the-shelf osteoarthritis stem cell therapy candidate.
Charles River Laboratories will supply GMP-grade Next Generation Sequencing (NGS) and viral safety release testing to Arovella Therapeutics for its ALA-101 CAR-iNKT cell therapy. The tie-up follows FDA acceptance of NGS-based viral safety testing in Arovella’s IND for treating CD19+ B-cell lymphomas and leukemias.
Roche has officially announced the launch of AXELIOS 1, a next-generation sequencing platform built on proprietary SBX technology, promising same-day whole-genome sequencing with unprecedented speed and accuracy.
